Ganot Ilan 4

What Happened

• Ilan Ganot, a director of Solid Biosciences (SLDB), had 4,861 restricted stock units (RSUs) convert into 4,861 common shares on Feb 13, 2026 (conversion/exercise, code M). Following the conversion, Ganot sold 2,658 of those shares in an open-market sell-to-cover transaction on Feb 18, 2026 for total proceeds of $15,478 (weighted average price $5.82). The conversion itself generated no cash proceeds (reported at $0).

Key Details

• Transaction dates and prices:
  • Feb 13, 2026: 4,861 RSUs converted to 4,861 common shares (one-for-one conversion; code M).
  • Feb 18, 2026: 2,658 shares sold (code S) at a weighted average price of $5.82, total proceeds $15,478. Sales prices ranged from $5.23 to $6.14.
• Shares owned after transaction: total reported holdings equal 118,691 shares (95,255 held individually, 4,042 held jointly with Annie Ganot, and 19,394 held in the Ilan Ganot 2017 Irrevocable Trust).
• Notable footnotes:
  • F1/F6: The shares resulted from RSUs that convert one-for-one; 19,444 RSUs were originally granted on Feb 13, 2024, vesting in four equal annual installments (4,861 per installment).
  • F3: The Feb 18 sale was a sell-to-cover to satisfy withholding taxes under a durable automatic sales instruction (not a discretionary trade).
  • F4: Reported sale price is a weighted average; detailed per-trade prices are available on request.
• Filing timeliness: Form 4 was filed Feb 18, 2026; no late-filing flag is indicated.

Context

• This was not a cash-buy; it was an RSU vesting event (conversion of equity award) followed by a sell-to-cover to satisfy taxes. Such sales to cover tax withholding are routine and do not necessarily indicate the insider’s view on the company’s prospects.
• Transaction codes: M = exercise or conversion of a derivative (here, RSU vesting/conversion); S = sale; the disposal of converted shares for $0 reflects the non-cash conversion of RSUs.